Cyril Amarchand Mangaldas advised Swiss Parenterals Limited in acquisition of 30% stake by Eris Lifesciences Limited
The leading law firm, Cyril Amarchand Mangaldas advised Swiss Parenterals Limited (“SPL”) and Mr. Naishadh Shah (“Seller”) in the proposed sale of the remaining 30% stake of SPL to Eris Lifesciences Limited (“ELL”) for an aggregate consideration of INR 423.30 crores. The consideration will be discharged by ELL through issuance and allotment of 23,06,372 equity shares (constituting 1.69% of ELL’s share capital) to the Seller via a preferential issue under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.
ELL, an Indian branded formulations company, had acquired a majority equity stake in SPL in 2024 to expand its sterile injectables footprint across 80+ emerging markets in Africa, the Asia Pacific, and Latin America. Upon completion of the proposed sale, subject to regulatory approvals, SPL will become a wholly owned subsidiary of ELL.
Cyril Amarchand Mangaldas’ General Corporate team reviewed and negotiated the share purchase and subscription agreement and related preferential allotment documents for SPL and the Seller, assisted with execution, and is supporting closing-related aspects of the transaction.
The Cyril Amarchand Mangaldas transaction team was led by Ravi Shah (Partner), with support from Arushi Bindal (Senior Associate) and Aesha Shah (Associate). The transaction was signed on November 24, 2025.
Click to know more about Cyril Amarchand Mangaldas
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at [email protected] or call us on +91 8879634922.